Table 2 Baseline Comorbidities, 1 year before Surgery
|  | cHP Cohort N = 1,069a | tHP Cohort N = 773 |
|---|---|---|
Cardiovascular and metabolic disorders | ||
Arrhythmias | 195 (18.2%) | 113 (14.6%) |
Congestive heart failure | 60 (5.6%) | 33 (4.3%) |
Diabetes | 225 (21.0%) | 175 (22.6%) |
Hypertension | 485 (45.4%) | 331 (42.8%) |
Central Nervous System | ||
Basal ganglia calcification | 0 (0.0%) | 0 (0.0%) |
Peripheral Neuropathy | 25 (2.3%) | 9 (1.2%) |
Seizures and convulsions | 21 (2.0%) | 10 (1.3%) |
Laboratory Imbalances | ||
Hypercalcemia | 142 (13.3%) | 144 (18.6%) |
Hypercalciuria | 9 (0.8%) | 5 (0.6%) |
Hypocalcemia | 77 (7.2%) | 8 (1.0%) |
Malignancy | ||
Any Malignancy | 457 (42.8%) | 265 (34.3%) |
Thyroid Cancer | 379 (35.5%) | 212 (27.4%) |
Musculoskeletal | ||
Fractures | 32 (3.0%) | 19 (2.5%) |
Osteoporosis | 95 (8.9%) | 50 (6.5%) |
Neuropsychiatric | ||
Anxiety | 236 (22.1%) | 165 (21.3%) |
Cognitive impairment | 27 (2.5%) | 15 (1.9%) |
Dementia | 10 (0.9%) | 6 (0.8%) |
Depressive disorders | 202 (18.9%) | 135 (17.5) |
Sleep-wake disorders | 190 (17.8%) | 115 (14.9%) |
Other | ||
Cataract formation | 0 (0.0%) | 0 (0.0%) |
Tetany | 2 (0.2%) | 1 (0.1%) |
Renal Disease | ||
CKD (Stage 1–4, unspecified) | 87 (8.1%) | 54 (7.0%) |
CKD Stage 5, ESRD and failure | 44 (4.1%) | 31 (4.0%) |
Diabetic Nephropathy | 87 (8.1%) | 59 (7.6%) |
Nephrolithiasis/renal stones | 65 (6.1%) | 54 (7.0%) |